You are the owner of this page.

DLH Reports Third Quarter Fiscal Year 2020 Results

ATLANTA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced financial results for its fiscal third quarter ended June 30, 2020. 


  • Revenue was $51.5 million for the third quarter versus $38.7 million for the prior-year period
  • Operating income was $3.8 million for the third quarter versus $1.7 million for the prior-year period
  • Earnings were $2.1 million, or $0.16 per diluted share, for the third quarter of fiscal 2020 versus $0.8 million, or $0.06 per diluted share, for the prior-year period; earnings before interest, tax, depreciation and amortization ("EBITDA") was $5.5 million for the third quarter of fiscal 2020 versus $2.6 million for the prior-year period
  • DLH generated $10.0 million of cash from operations during the quarter and reduced the Company's debt to $44.5 million from $55.0 million at March 31, 2020
  • The Company also recently announced awards of more than $15 million for trials and studies related to COVID-19

Management Discussion
“I’m very pleased to report that, in the midst of a global pandemic, DLH has continued to generate solid financial results and strengthen its outlook,” stated DLH President and Chief Executive Officer Zach Parker. “We posted operating margins of 7.4%, generated $10.0 million of cash from operations, and again paid down debt – reducing it by nearly 20% from second quarter levels. We also brought on Jeanine Christian as President of our S3 operating unit and Jackie Everett as Chief Growth Officer; both Jeanine and Jackie bring seasoned leadership experience, broad customer relationships, and analytical skills honed within the scientific community. We are confident they will be instrumental to our continued success going forward.

“In addition, we recently received contracts to assist the National Institutes of Health in their fight against infectious diseases – in this case, COVID-19. With recent awards expected to generate approximately $15 million in calendar 2020, we will evaluate multiple therapeutic products and manage a consortium of partners to conduct trials in a rapid and efficient manner. Wins like this not only underscore the value of our expertise and relationships with key government agencies, they bolster the outlook for our Company at a time when the U.S. – and world – are seeking leadership in identifying and producing treatments to battle the continuing pandemic. I’m proud of DLH’s role in this fight and the assistance we’re providing towards getting a cure to market as soon as possible.”

Results for the Three Months Ended June 30, 2020
Revenue for the third quarter of fiscal 2020 was $51.5 million versus $38.7 million in the prior-year period. The significant increase was due primarily to the inclusion of revenue from the Social & Scientific Systems operating unit ("S3") for the full quarter, versus inclusion for three weeks in the prior-year period following the June 2019 acquisition.

Income from operations was $3.8 million for the quarter versus $1.7 million in the prior-year period and, as a percent of revenue, the Company reported an operating margin of 7.4% in fiscal 2020 versus 4.4% in fiscal 2019, reflecting stronger operating results, partly offset by increased amortization from acquired intangibles.  Interest expense in the quarter was $0.8 million, versus $0.6 million for the three months ended June 30, 2019, due to the borrowing required to finance the S3 acquisition. Income before taxes was $3.0 million for the quarter versus $1.1 million in fiscal 2019, representing 5.8% and 2.9% of revenue, respectively, for each quarter.

For the three months ended June 30, 2020, DLH recorded a $0.9 million provision for tax expense versus $0.3 million in the prior-year period. The Company reported net income of approximately $2.1 million, or $0.16 per diluted share, for the third quarter of fiscal 2020 versus $0.8 million, or $0.06 per diluted share, for the third quarter of fiscal 2019. As a percent of revenue, net income was 4.1% for the third quarter of fiscal 2020 versus 2.1% for the prior-year period.

On a non-GAAP basis, EBITDA for the three months ended June 30, 2020 was approximately $5.5 million versus $2.6 million in the prior-year period, resulting in 10.7% and 6.7% as a percentage of revenue for each respective year. The year-over-year increase was primarily due to the impact of the S3 acquisition, including the improved operating leverage achieved through the expansion of the Company's business base, as well as growth across the Company’s legacy operations. 

Balance Sheet and Cash Flow
DLH generated  $10.0 million in operating cash during the third quarter of fiscal 2020, largely reflecting improved profitability and a reduction in accounts receivable. The Company anticipates continued strong operating cash flow for the remainder of fiscal 2020, and projects a debt balance of $40 to $42 million at fiscal year-end.

As of June 30, 2020, the Company had cash and cash equivalents of $0.7 million and debt outstanding of $44.5 million, versus cash of $1.8 million and debt outstanding of $56.0 million as of September 30, 2019. The next required principal payment is not due until September 2023, although the Company intends to continue using free cash flow to make prepayments when possible.

Conference Call and Webcast Details
DLH management will discuss third quarter results and provide a general business update, including current competitive conditions and strategies, during a conference call beginning at 11:00 AM Eastern Time tomorrow, August 6, 2020. Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256.  Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. 

A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 10146068.

About DLH
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company's seven core competencies include secure data analytics, clinical trials and laboratory services, case management, performance evaluation, system modernization, operational logistics and readiness, and strategic digital communications. DLH has over 2,000 employees serving numerous government agencies. For more information, visit the corporate website at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance.  Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of an acquisition; the challenges of managing larger and more widespread operations resulting from the acquisition; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations of future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2019, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business.  Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.


Contact: Chris Witty
Phone:  646-438-9385


(Amounts in thousands except per share amounts)

  Three Months Ended Nine Months Ended
  June 30, June 30,
  2020 2019 2020 2019
Revenue $51,459   $38,700   $158,495   $106,208  
Cost of Operations:        
Contract costs 39,615   30,038   123,895   82,744  
General and administrative costs 6,323   4,811   18,497   13,462  
Acquisition costs —   1,247   —   1,391  
Depreciation and amortization 1,721   914   5,340   2,037  
Total operating costs 47,659   37,010   147,732   99,634  
Income from operations 3,800   1,690   10,763   6,574  
Interest expense, net 813   562   2,659   1,284  
Income before income taxes 2,987   1,128   8,104   5,290  
Income tax expense 863   325   2,352   1,207  
Net income $2,124   $803   $5,752   $3,758  
Net income per share - basic $0.17   $0.07   $0.47   $0.31  
Net income per share - diluted $0.16   $0.06   $0.44   $0.29  
Weighted average common shares outstanding        
Basic 12,354   12,036   12,246   12,011  
Diluted 13,228   13,077   13,050   13,048  

(Amounts in thousands except par value of shares)

  June 30,
 September 30,
Current assets:    
Cash and cash equivalents $658    $1,790   
Accounts receivable 29,635    23,226   
Other current assets 3,772    1,831   
Total current assets 34,065    26,847   
Equipment and improvements, net 3,769    5,343   
Operating lease right-of-use assets 22,276    —   
Deferred taxes, net 358    2,345   
Goodwill 52,758    52,758   
Intangible assets, net 37,594    41,208   
Other long-term assets 620    757   
Total assets $151,440    $129,258   
Current liabilities:    
Operating lease liabilities - current $1,768    $—   
Accrued payroll 9,488    8,852   
Accounts payable, accrued expenses, and other current liabilities 24,253    20,633   
Total current liabilities 35,509    29,485   
Long-term liabilities:    
Debt obligations - long term, net of deferred financing costs 42,542    53,629   
Operating lease liabilities - long-term 21,686    —   
Other long-term liabilities —    573   
Total long-term liabilities 64,228    54,202   
Total liabilities 99,737    83,687   
Shareholders' equity:    
Common stock, $0.001 par value; authorized 40,000 shares; issued and outstanding 12,354 and 12,036 at June 30, 2020 and September 30, 2019, respectively 12    12   
Additional paid-in capital 85,496    85,114   
Accumulated deficit (33,805)  (39,555) 
Total shareholders’ equity 51,703    45,571   
Total liabilities and shareholders' equity $151,440    $129,258   

(Amounts in thousands)

  Nine Months Ended
  June 30,
  2020 2019
Operating activities    
Net income $5,752    $3,758   
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 5,340    2,037   
Amortization of deferred financing costs 551    799   
Stock based compensation expense 566    591   
Deferred taxes, net 1,987    1,253   
Non-cash gain from lease modification (121)  —   
Changes in operating assets and liabilities    
Accounts receivable (6,409)  (925) 
Other current assets (1,941)  (376) 
Accrued payroll 636    (68) 
Accounts payable, accrued expenses, and other current liabilities 3,620    4,107   
Other long-term assets/liabilities 726    (23) 
Net cash provided by operating activities 10,707    11,153   
Investing activities    
Business acquisition, net of cash acquired —    (66,520) 
Purchase of equipment and improvements (152)  (29) 
Net cash used in investing activities (152)  (66,549) 
Financing activities    
Borrowing on senior debt —    70,000   
Repayments of senior debt (11,500)  (11,646) 
Payment of debt financing costs (3)  (3,347) 
Repurchase of common stock (211)  —   
Proceeds from issuance of common stock upon exercise of options 27    39   
Net cash (used in) provided by financing activities (11,687)  55,046   
Net change in cash and cash equivalents (1,132)  (350) 
Cash and cash equivalents at beginning of year 1,790    6,355   
Cash and cash equivalents at end of year $658    $6,005   
Supplemental disclosures of cash flow information    
Cash paid during the period for interest $2,207    $645   
Cash paid during the period for income taxes $432    $675   

Revenue Metrics

  Nine Months Ended
  June 30, June 30,
  2020 2019
Market Mix:     
Defense/VA 48 % 66 %
Human Services and Solutions 20 % 28 %
Public Health/Life Sciences 32 % %
Contract Mix:    
Time and materials 70 % 93 %
Cost reimbursable 28 % %
Firm fixed price % %
Prime vs Sub:    
Prime 93 % 98 %
Subcontractor % %

Non-GAAP Financial Measures
The Company uses EBITDA and EBITDA as a percent of revenue as supplemental non-GAAP measures of our performance. We define EBITDA as net income excluding (i) interest expense, (ii) provision for or benefit from income taxes and (iii) depreciation and amortization. EBITDA as a percent of revenue is EBITDA for the measurement period divided by revenue for the same period.

These non-GAAP measures of performance are used by management to conduct and evaluate its business during its review of operating results for the periods presented. Management and the Company's Board utilize these non-GAAP measures to make decisions about the use of the Company's resources, analyze performance between periods, develop internal projections and measure management performance. We believe that these non-GAAP measures are useful to investors in evaluating the Company's ongoing operating and financial results and understanding how such results compare with the Company's historical performance.

Reconciliation of GAAP net income to EBITDA, a non-GAAP measure:

(amounts in thousands) Three Months Ended Nine Months Ended
  June 30, June 30,
  2020 2019 Change 2020 2019 Change
Net income $2,124   $803   $1,321   $5,752   $3,758   $1,994  
(i) Interest expense, net 813   562   251   2,659   1,284   1,375  
(ii) Provision for taxes 863   325   538   2,352   1,532   820  
(iii) Depreciation and amortization 1,721   914   807   5,340   2,037   3,303  
EBITDA $5,521   $2,604   $2,917   $16,103   $8,611   $7,492  
EBITDA as a % of revenue 10.7 % 6.7 % 4.0 % 10.2 % 8.1 % 2.1 %
Revenue $51,459   $38,700   $12,759   $158,495   $106,208   $52,287  

In fiscal 2019, the Company incurred $1.4 million of acquisition-related expenses during the nine months ended June 30, 2019 for the acquisition of S3. The Company is excluding acquisition-related expenses from this measure because they were incurred as a result of a specific event, do not reflect the costs of our operations, and can affect the period-over-period assessment of operating results. In addition, we are including net income adjusted for the acquisition of S3, in total and on a per share basis, presented on a tax-effected basis. We are reporting this non-GAAP metric to demonstrate the impact of these events.

Reconciliation of GAAP net income to net income adjusted for the effect of the acquisition costs, a non-GAAP measure:

  Three Months Ended Nine Months Ended
  June 30, June 30,
  2020 2019 Change 2020 2019 Change
Net income $2,124   $803    $1,321    $5,752   $3,758    $1,994   
Acquisition costs —   1,247    (1,247)  —   1,391    (1,391) 
Tax effect of excluding acquisition costs —   (362)  362    —   (403)  403   
Net income adjusted for the acquisition costs $2,124   $1,688    $436    $5,752   $4,746    $1,006   
Net income per diluted share $0.16   $0.06    $0.10    $0.44   $0.29    $0.15   
Impact of acquisition —   0.07    (0.07)  —   0.08    (0.08) 
Net income adjusted for the acquisition costs $0.16   $0.13    $0.03    $0.44   $0.37    $0.07   

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.